CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc., a biotechnology company pioneering the development of therapeutic synthetic life, today announced that the company will be presenting scientific and corporate updates at several upcoming conferences, detailed below. For the first time, the Company will be releasing in vivo efficacy data highlighting the recent successes achieved with the Company’s two lead programs in development to treat the orphan genetic metabolic conditions Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Help employers find you! Check out all the jobs and post your resume.
